Compare Sea Limited (SE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sea Limited vs Vertex Pharmaceuticals Incorporated — how do they compare? Sea Limited trades at $106.26 (market cap $64.73B), while Vertex Pharmaceuticals Incorporated trades at $478.06 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals.
| SE | VRTX | |
|---|---|---|
Market Cap | $64.73B | $121.95B |
Sector | Media | Health |
52-Week High | $196.50 | $529.59 |
52-Week Low | $78.16 | $366.54 |
Enterprise Value | $57.78B | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sea Limited (SE) trades at $106.26, up 2.12% with a neutral technical signal. The company shows strong revenue growth, reaching $22.94 billion in 2025 with a net income margin of 6.36%. Recent earnings beat expectations in Q1 2026 but missed in prior quarters. Analyst sentiment remains bullish with a $131 consensus price target, though insider selling has drawn attention amid a 30% stock decline over the past year.
The outlook is mixed: robust fundamentals and analyst support suggest upside potential, but risks include earnings volatility, competitive pressures, and geopolitical factors affecting sentiment. The stock's valuation at a P/E of 41.61 requires sustained growth to justify current levels, making execution critical for future performance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
